The Leader in Brachytherapy
With higher energy and a shorter half-life than competitors, Cesium Blu by Isoray is proven to be a highly customized and effective treatment for the rapid recovery of patients in the fight against prostate cancer.
Isoray is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers.
Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells.
Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.
The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized.
In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.
The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses.
In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement.
Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising.
Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer.
Join Us at the Following Events
10/24/2021 - 10/27/2021
11/18/2021 - 11/20/2021
Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed...
South Florida Hospital News & Healthcare Report with Chief Research & Development Officer Bill Cavanagh and prominent doctors on treating cancers with Cesium-131
To read the full article below, please use the navigation arrows at the bottom of each page which become visible when you place your cursor at the bottom of each page. ...
Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON –October 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131
RICHLAND, WASHINGTON – September 28, 2021 – The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131...
Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues
Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options...